Novartis discloses seven new tumor cases in Zolgensma patients, two possibly linked

Novartis has disclosed seven new tumor cases in patients treated with its spinal muscular atrophy gene therapy, Zolgensma, and says two may be linked to the therapy. This brings the total acknowledged to nine since the drug's approval in 2019; more than 6,000 patients have been treated across clinical trials and commercial use.

Detected & updated continuously · Source: Nebula